DUBLIN, July 27, 2011 /PRNewswire/ —
Shire plc (LSE: SHP, NASDAQ:
SHPGY), the global specialty biopharmaceutical company,
announces that Susan Kilsby will join the Board of Directors on
September 1st, 2011. On joining the Board, Ms
Kilsby will become a member of the Company’s Audit, Compliance
& Risk Committee.
In addition, current Board Directors Bill Burns and David Stout
will join the Nomination Committee and Remuneration Committee
respectively with immediate effect.
Susan Kilsby has a distinguished global career in investment
banking having held senior positions with The First Boston
Corporation, Bankers Trust, Barclays de Zoete Wedd and most
recently Credit Suisse where she was Chairman of the EMEA Mergers
& Acquisitions team until 2009 and continues in a part-time
senior advisory role.
An American national with UK citizenship, Ms Kilsby gained her
first degree in Economics at Wellesley College and her MBA at Yale
School of Management.
Ms Kilsby has been a non executive director of Hong Kong-listed
global skin care company, L’Occitane International S.A. since
January 2010.
Shire Chairman, Matt Emmens, comments:
“Susan’s impressive experience of investment banking and finance
across global markets will be a welcome addition to our Board.”
Susan Kilsby adds:
“Shire is a leading light in the pharmaceutical world and has a
very exciting future ahead; I’m delighted to have the opportunity
to make a contribution to this future and to join such a strong
team with diverse backgrounds and knowledge.”
There is no further information that is required to be disclosed
under 9.6.13R of the UK Listing Rules.
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the
specialist physicia
‘/>”/>
